Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms

Hollmén, Maija; Määttä, Jorma A.; Bald, Laura; Sliwkowski, Mark X.; Elenius, Klaus

doi:10.1038/onc.2008.481

Cited by 53 publications

(54 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[18][19][20][21] An explanation for conflicting observations may be that different isoforms and the subcellular localizations of ERBB4 differ in function. Analyzing functionally dissimilar isoforms can complicate the cancer biology of ERBB4.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…18,23,24 In addition, some researchers have not distinguished between the membranous, cytoplasmic, and nuclear expression of ERBB4 in evaluating clinical outcomes. 25 In the present study, ERBB4 expression was predominantly localized to the cytoplasm in all ovarian serous carcinoma samples.…”

Section: Discussionmentioning

confidence: 99%

ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy

et al. 2017

View full text Add to dashboard Cite

“…Additionally, ERBB4 likely induces cell survival through more than one pathway; for example, the antiapoptotic response to high levels of overexpression and heterodimerization with EGFR depend on COX-2 activity (4), whereas modest, selective ERBB4 activation with its specific ligand NRG4 protects cells from cytokine-induced death in a COX-2 independent manner (7). Further study is required to distinguish between these two possibilities and thus define the potential utility of isoform-specific targeting approaches as have been proposed for some cancers (55).…”

Section: Discussionmentioning

confidence: 99%

ERBB4 is over-expressed in human colon cancer and enhances cellular transformation

Williams

Bernard

Beckler

et al. 2015

CARCIN

View full text Add to dashboard Cite

The ERBB4 receptor tyrosine kinase promotes colonocyte survival. Herein, we tested whether ERBB4's antiapoptotic signaling promotes transformation and colorectal tumorigenesis. ERBB4 alterations in a The Cancer Genome Atlas colorectal cancer (CRC) data set stratified survival, and in a combined Moffitt Cancer Center and Vanderbilt Medical Center CRC expression data set, ERBB4 message levels were increased at all tumor stages. Similarly, western blot and immunohistochemistry on additional CRC tissue banks showed elevated ERBB4 protein in tumors. ERBB4 was highly expressed in aggressive, dedifferentiated CRC cell lines, and its knockdown in LIM2405 cells reduced anchorage-independent colony formation. In nude mouse xenograft studies, ERBB4 alone was insufficient to induce tumor establishment of non-transformed mouse colonocytes, but its overexpression in cells harboring Apc min and v-Ha-Ras caused a doubling of tumor size. ERBB4-expressing xenografts displayed increased activation of survival pathways, including epidermal growth factor receptor and Akt phosphorylation and COX-2 expression, and decreased apoptotic signals. Finally, ERBB4 deletion from mouse intestinal epithelium impaired stem cell replication and in vitro enteroid establishment. In summary, we report that ERBB4 is over-expressed in human CRC, and in experimental systems enhances the survival and growth of cells driven by Ras and/or WNT signaling. Chronic ERBB4 overexpression in the context of, for example, inflammation may contribute to colorectal carcinogenesis. Tumors with high receptor levels are likely to have enhanced cell survival signaling through epidermal growth factor receptor, PI3K and COX-2. These results suggest ERBB4 as a novel therapeutic target in a subset of CRC.

show abstract

“…Whether genetic or sporadic in origin, the conversion of normal cells to malignant cancer cells requires multiple alterations at both the gene and chromosome levels (Hollmen et al, 2009 andTovey et al, 2006). Evidence in favor of this concept comes from the observation of multiple genetic alterations such as deletions, insertions, amplifications, rearrangement, recombination and point mutations in the tumor genome.…”

Section: Introductionmentioning

confidence: 99%

Early Diagnosis of Breast Cancer using Molecular, Biochemical and Pathological Markers

El-Assal¹

2011

American Journal of Applied Sciences

View full text Add to dashboard Cite

Problem statement: Laboratory diagnosis of breast cancer in most of the hospitals has traditionally been performed using cell culture and the direct hormone receptor assay, which are money and time consuming. Approach: This study was performed in order to direct the attention toward increasing the efficiency of early diagnosis in clinical laboratories at the western region of KSA and Egypt using recent PCR-dependent protocols i.e., Randomly Amplified Polymorphic DNA (RAPD's) and Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR). Expression of HER4 oncogene using RT-PCR and immunohistochemical (IHC) staining have been assessed as early diagnostic for breast cancer. RT-PCR has detected HER4 expression in 52% of Invasive Duct breast Cancer (IDC) and this expression was significantly correlated with HER4 gene expression by IHC. Also we have selected sixteen 10-mer RAPD primers that have shown high percentage of identity to exons of different human oncogenes, such as V-myc, HER2, HER4, BRCA1 and BRCA2. Results: Only 13 out of the selected RAPD primers have revealed 19 distinguishable polymorphic markers between patient and normal females. Moreover, analysis of total protein profile identified extra markers and some differences at the level of Low Molecular Weight (LMW) protein among the two classes of females. Conclusion: These data will provide molecular, biochemical and pathological markers that can be used in KSA and Egypt clinical laboratories as additional efficient tools for early diagnosis of breast cancer.

show abstract

Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms

Cited by 53 publications

References 39 publications

ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy

ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy

ERBB4 is over-expressed in human colon cancer and enhances cellular transformation

Early Diagnosis of Breast Cancer using Molecular, Biochemical and Pathological Markers

Contact Info

Product

Resources

About